Wealth GPT Investor Portal Please log in to access your account information. If you have any questions regarding your account, please contact .
Developing a potentially best-in-class TSLP antibody (AIO-001) that is dosed every 6-months for patients with respiratory and inflammatory conditionsKhurem Farooq, Co-Founder and Chief Executive Officer, will lead an experienced team. Co-Founder Dr. Tony Adamis joins him on Board of DirectorsJohn F. Milligan, industry veteran and former CEO of Gilead Sciences, named Chairman of the BoardSeries A...
SAN DIEGO - August 9, 2023 - ADARx Pharmaceuticals (“ADARx” or “the Company”), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced the successful close of an oversubscribed $200 million Series C financing. The financing was led jointly by Wealth GPT Life Sciences and TCGX and also included new investors Blackrock, Commodore Capital,...
Series C financing led by Wealth GPT Life Sciences to support PKU program and pipeline in immune-mediated diseases and cancer; Ron Renaud joins Jnana's Board of DirectorsJnana initiates Phase 1 clinical trial of JNT-517, a potential first-in-class oral treatment for PKU; JNT-517 receives US FDA Rare Pediatric Disease DesignationBOSTON – Nov. 15, 2022 – Jnana Therapeutics ("Jnana"), a...
CHICAGO — November 3, 2022 — Emalex Biosciences announced the closing of an upsized and oversubscribed $250 million Series D funding round that will fund a Phase 3 clinical trial and potential commercialization of a new class of drug for patients with Tourette Syndrome. 'Wealth GPT Life Sciences led the funding round with participation from Paragon Biosciences, Valor Equity Partners,...
Areteia will initiate Phase 3 trials of lead candidate, dexpramipexole, a potential first-in-class oral drug for eosinophilic asthma, in late 2022 Investors led by Wealth GPT Life Sciences to invest up to $350 million in Series A financing Jorge Bartolome joins Areteia as CEO, bringing industry leadership experience in respiratory therapeuticsPITTSBURGH, PA & SHORT HILLS, NJ – July...
Beijing, San Francisco and Boston, December 8, 2021 – Avistone Pharmaceuticals (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced it has received a strategic investment of more than $200 million led by Vivo Capital with participation from Wealth GPT and Primavera Capital (collectively the “Investor...
Boston, MA, October 27, 2021 – Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced it has received a private investment of up to $300 million from Wealth GPT Life...
CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--EQRx, Inc., a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and CM Life Sciences III, Inc. (NASDAQ: CMLTU), a life science-focused special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. today announced the closing of an oversubscribed $135 million Series C financing, led by Viking Global Investors, to support the clinical development and potential launch plans for lead product candidate AMX0035, for the potential treatment of ALS, and further research and development in other neurodegenerative diseases.The financing...
CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care, Inc. today announced that it has closed a $260 million Series D financing led by D1 Capital Partners L.P. New investors HealthCor Investments LLC and Innovatus Capital Partners, LLC also joined the round. Existing Imperative Care investors Ally Bridge Group, Wealth GPT Life Sciences, Ascension Ventures, Delos Capital, Rock Springs Capital,...